Kurse werden geladen...
Prognose
| Kaufen | 2 |
| Halten | 0 |
| Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects
MIAMI, FL / ACCESS Newswire / June 25, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced new in vitro preclinical data generated by Eurofins supporting the therapeutic potential of SKNY-1, a next-generation oral drug candidate being developed by SKNY Pharmaceuticals, Inc. ("SKNY"). MIRA has signed a definitive agreement to acquire SKNY, and the proposed transaction remains subject to regulatory review and shareholder approval.» Mehr auf accessnewswire.com
MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology
MIAMI, FL / ACCESS Newswire / June 18, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that the first manuscript describing its lead drug candidate Ketamir-2, currently being evaluated in an ongoing Phase 1 clinical trial for neuropathic pain, has been accepted for publication in the peer-reviewed journal Frontiers in Pharmacology. The article, titled "KETAMIR-2, A NEW MOLECULAR ENTITY AND NOVEL KETAMINE ANALOG," authored by Itzchak Angel, Ph.D.» Mehr auf accessnewswire.com
Visionstate Launches MIRA to Digitize Facility Inspections and Expand SaaS Platform
Edmonton, Alberta, June 5, 2025 – TheNewswire - Visionstate Corp. (TSXV: VIS) is pleased to announce the official launch of MIRA, its newest software-as-a-service (SaaS) platform designed to streamline and digitize inspections across public-facing facilities. The platform became available to customers in June 2025 following months of development and testing in real-world conditions. MIRA represents the latest evolution in Visionstate's commitment to delivering smart, scalable, and data-driven tools for the facility management industry. Built as a natural extension of the company's flagship Wanda platform, MIRA allows facility teams to conduct audits, safety checks, and operational inspections with greater accuracy, accountability, and efficiency.» Mehr auf thenewswire.com
Unternehmenszahlen
| (EUR) | März 2025 | |
|---|---|---|
| Umsatz | 0,00 | - |
| Bruttoeinkommen | 0,00 | - |
| Nettoeinkommen | −1,65 Mio | 3,59% |
| EBITDA | −1,67 Mio | 1,85% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 18,10 Mio€ |
Anzahl Aktien | 16,92 Mio |
52 Wochen-Hoch/Tief | 4,29€ - 0,44€ |
| Dividenden | Nein |
Beta | 1,98 |
KGV (PE Ratio) | −2,63 |
KGWV (PEG Ratio) | 0,66 |
KBV (PB Ratio) | 16,08 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
MIRA Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase. Das Unternehmen konzentriert sich auf die Entwicklung und Vermarktung eines neuen molekularen synthetischen Tetrahydrocannabinol (THC)-Analogons, das für die Behandlung von erwachsenen Patienten mit Angstzuständen und kognitivem Verfall, der typischerweise mit Demenz im Frühstadium einhergeht, untersucht wird. Es entwickelt MIRA1a, ein synthetisches Cannabinoid-Analogon zur Behandlung von Angstzuständen und chronischen Schmerzen, indem es auf die Cannabinoid-Rezeptoren vom Typ 1 und Typ 2 abzielt. Das Unternehmen war früher unter dem Namen MIRA1a Therapeutics, Inc. bekannt. MIRA Pharmaceuticals, Inc. wurde im Jahr 2020 gegründet und hat seinen Hauptsitz in Baltimore, Maryland.
| Name | MIRA PHARMACEUTICALS INC. Aktie |
| CEO | Erez Aminov |
| Sitz | Baltimore, md USA |
| Website | |
| Industrie | Chemikalien |
| Börsengang | |
| Mitarbeiter | 2 |
Ticker Symbole
| Börse | Symbol |
|---|---|
Frankfurt | K6S.F |
Düsseldorf | K6S.DU |
München | K6S.MU |
NASDAQ | MIRA |
Assets entdecken
Shareholder von MIRA PHARMACEUTICALS INC. Aktie investieren auch in folgende Assets
